18F-Fluoromisonidazole PET in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting With Tumefactive Demyelinating Lesion.
18F-Fluoromisonidazole PET in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting With Tumefactive Demyelinating Lesion.
复制标题
18F-氟罗米索硝唑 PET 在髓磷脂少突胶质细胞糖蛋白抗体相关疾病中的表现，表现为肿瘤性脱髓鞘病变。
DOI：
10.1097/rlu.0000000000003429
复制
发表时间：
2021
影响因子：
10.6
通讯作者：
Nishiyama Y.
中科院分区：
文献类型：
--
作者：
Mitamura K;Norikane T;Takata T;Yamamoto Y;Nishiyama Y.
肿胀性脱髓鞘病变已被认为是髓鞘少突胶质细胞糖蛋白抗体相关疾病的临床和放射学谱的一部分。一名63岁的妇女进行了后续的髓鞘少突胶质细胞糖蛋白抗体相关疾病。两年后，她出现了右侧面瘫。T2加权MRI扫描显示右侧额叶高信号区伴水肿改变，增强T1加权图像显示部分强化。该对比增强区域显示18 F-氟咪唑摄取增加。
Tumefactive demyelinating lesions have been appreciated as part of the clinical and radiological spectrum of myelin oligodendrocyte glycoprotein antibody–associated disease. A 63-year-old woman was followed up for myelin oligodendrocyte glycoprotein antibody–associated disease. Two years later, she presented with right facial paralysis. T2-weighted MRI scan demonstrated a high-signal-intensity area with edematous change in the right frontal lobe, and partial enhancement was shown on contrast-enhanced T1-weighted image. This contrast-enhanced area showed increased 18 F-fluoromisonidazole uptake.
18F-FET PET 对疑似肿瘤性脱髓鞘疾病患者的价值——回顾性分析的初步经验
影响因子：
10.6
作者：
M. Barbagallo;A. Albatly;S. Schreiner;Helen Hayward;A. Buck;S. Kollias;M. Huellner
通讯作者：
M. Huellner
使用 18F-GE-180 的 TSPO PET 可区分多发性硬化症的变体：复发缓解型多发性硬化症、肿瘤性脱髓鞘病和 Baló 同心圆硬化症。
影响因子：
10.6
作者：
Stefanie Völk;M. Unterrainer;N. Albert;J. Havla;L. Gerdes;Minh Schumacher;M. Brendel;L. Kaiser;K. Adorjan;R. Rupprecht;P. Bartenstein;T. Kümpfel;A. Danek
通讯作者：
A. Danek